Literature DB >> 23768628

Huntington's disease: underlying molecular mechanisms and emerging concepts.

John Labbadia1, Richard I Morimoto.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder for which no disease modifying treatments exist. Many molecular changes and cellular consequences that underlie HD are observed in other neurological disorders, suggesting that common pathological mechanisms and pathways may exist. Recent findings have enhanced our understanding of the way cells regulate and respond to expanded polyglutamine proteins such as mutant huntingtin. These studies demonstrate that in addition to effects on folding, aggregation, and clearance pathways, a general transcriptional mechanism also dictates the expression of polyglutamine proteins. Here, we summarize the key pathways and networks that are important in HD in the context of recent therapeutic advances and highlight how their interplay may be of relevance to other protein folding disorders.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Huntington's disease; molecular mechanisms; therapeutic approaches

Mesh:

Substances:

Year:  2013        PMID: 23768628      PMCID: PMC3955166          DOI: 10.1016/j.tibs.2013.05.003

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  85 in total

Review 1.  Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications.

Authors:  Francesca Cicchetti; Denis Soulet; Thomas B Freeman
Journal:  Brain       Date:  2011-01-28       Impact factor: 13.501

Review 2.  Autophagy gone awry in neurodegenerative diseases.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

4.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

5.  Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease.

Authors:  John Labbadia; Helen Cunliffe; Andreas Weiss; Elena Katsyuba; Kirupa Sathasivam; Tamara Seredenina; Ben Woodman; Saliha Moussaoui; Stefan Frentzel; Ruth Luthi-Carter; Paolo Paganetti; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

6.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.

Authors:  J S Steffan; L Bodai; J Pallos; M Poelman; A McCampbell; B L Apostol; A Kazantsev; E Schmidt; Y Z Zhu; M Greenwald; R Kurokawa; D E Housman; G R Jackson; J L Marsh; L M Thompson
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

7.  Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.

Authors:  Ehud Cohen; Johan F Paulsson; Pablo Blinder; Tal Burstyn-Cohen; Deguo Du; Gabriela Estepa; Anthony Adame; Hang M Pham; Martin Holzenberger; Jeffery W Kelly; Eliezer Masliah; Andrew Dillin
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

8.  Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.

Authors:  Judit Pallos; Laszlo Bodai; Tamas Lukacsovich; Judith M Purcell; Joan S Steffan; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2008-09-01       Impact factor: 6.150

9.  Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.

Authors:  Wenjun Song; Jin Chen; Alejandra Petrilli; Geraldine Liot; Eva Klinglmayr; Yue Zhou; Patrick Poquiz; Jonathan Tjong; Mahmoud A Pouladi; Michael R Hayden; Eliezer Masliah; Mark Ellisman; Isabelle Rouiller; Robert Schwarzenbacher; Blaise Bossy; Guy Perkins; Ella Bossy-Wetzel
Journal:  Nat Med       Date:  2011-02-20       Impact factor: 53.440

10.  Progressive disruption of cellular protein folding in models of polyglutamine diseases.

Authors:  Tali Gidalevitz; Anat Ben-Zvi; Kim H Ho; Heather R Brignull; Richard I Morimoto
Journal:  Science       Date:  2006-02-09       Impact factor: 63.714

View more
  131 in total

1.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

2.  Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.

Authors:  Motomasa Tanaka; Koko Ishizuka; Yoko Nekooki-Machida; Ryo Endo; Noriko Takashima; Hideyuki Sasaki; Yusuke Komi; Amy Gathercole; Elaine Huston; Kazuhiro Ishii; Kelvin Kai-Wan Hui; Masaru Kurosawa; Sun-Hong Kim; Nobuyuki Nukina; Eiki Takimoto; Miles D Houslay; Akira Sawa
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

Review 3.  Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.

Authors:  John Douglas Cleary; Laura P W Ranum
Journal:  Curr Opin Genet Dev       Date:  2014-05-22       Impact factor: 5.578

4.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

5.  Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.

Authors:  Sonal Agrawal; Julia Fox; Baskaran Thyagarajan; Jonathan H Fox
Journal:  Free Radic Biol Med       Date:  2018-04-04       Impact factor: 7.376

Review 6.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 7.  [Huntington's disease].

Authors:  J D Rollnik
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

8.  Combating Parkinson's disease-associated toxicity by modulating proteostasis.

Authors:  Yangshin Park; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 10.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.